Evaluation of the appropriateness of imipenem/cilastatin prescription and dosing in a tertiary care hospital

Background Imipenem/cilastatin is an antibacterial agent of the carbapenem class of β-lactams that is known to have an extremely wide spectrum of activity against Gram-positive, Gram-negative, aerobic, anaerobic, and even multidrug-resistant strains. The objective of this study was to evaluate the a...

Full description

Saved in:
Bibliographic Details
Main Author: Kabbara, Wissam K. (author)
Other Authors: Nawas, George T. (author), Ramadan, Wijdan H. (author)
Format: article
Published: 2015
Online Access:http://hdl.handle.net/10725/4482
http://dx.doi.org/10.2147/IDR.S78633
http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4378284/
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1864513463656644608
author Kabbara, Wissam K.
author2 Nawas, George T.
Ramadan, Wijdan H.
author2_role author
author
author_facet Kabbara, Wissam K.
Nawas, George T.
Ramadan, Wijdan H.
author_role author
dc.creator.none.fl_str_mv Kabbara, Wissam K.
Nawas, George T.
Ramadan, Wijdan H.
dc.date.none.fl_str_mv 2015
2016-10-03T08:10:14Z
2016-10-03T08:10:14Z
2016-10-03
dc.identifier.none.fl_str_mv 1178-6973
http://hdl.handle.net/10725/4482
http://dx.doi.org/10.2147/IDR.S78633
Kabbara, W. K., Nawas, G. T., & Ramadan, W. H. (2015). evaluation of the appropriateness of imipenem/cilastatin prescription and dosing in a tertiary care hospital. Infection and drug resistance, 8, 31.
http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4378284/
dc.language.none.fl_str_mv en
dc.relation.none.fl_str_mv Infection and Drug Resistance
dc.rights.*.fl_str_mv info:eu-repo/semantics/openAccess
dc.title.none.fl_str_mv Evaluation of the appropriateness of imipenem/cilastatin prescription and dosing in a tertiary care hospital
dc.type.none.fl_str_mv Article
info:eu-repo/semantics/publishedVersion
info:eu-repo/semantics/article
description Background Imipenem/cilastatin is an antibacterial agent of the carbapenem class of β-lactams that is known to have an extremely wide spectrum of activity against Gram-positive, Gram-negative, aerobic, anaerobic, and even multidrug-resistant strains. The objective of this study was to evaluate the appropriate use of imipenem/cilastatin in a local tertiary care hospital. The study assessed the indication both empirically and after the culture results were available, the dose and dose adjustment in renal failure, as well as the incidence of seizure in hospitalized patients receiving imipenem/cilastatin. Methods This observational study was conducted in a tertiary care hospital over a 3-month period. The treatment of 100 patients with imipenem/cilastatin was evaluated both empirically and after culture results were available. Analysis of the appropriateness of imipenem/cilastatin indication, dose, and monitoring of seizure frequency was based on the package insert, updated published guidelines, and clinical judgment. Results Patients from internal medicine and intensive care units comprised approximately 50% of the population in the study. The patients received imipenem/cilastatin mainly for urinary tract infections (27%) or for sepsis of an unknown focus (22%). The use of imipenem/cilastatin empirically was appropriate in 97.2% (n=69/71) of the cases, and its use postculture in 86% of the cases. There were 29% of the patients who were not started on imipenem/cilastatin empirically. Four patients out of the 29 patients (13.8%) who were not started on imipenem/cilastatin empirically inappropriately received imipenem/cilastatin post-culture results. Thirty-three patients (33%) were not dosed appropriately, 30 of whom had renal impairment and creatinine clearance fluctuations. Only one patient developed a seizure while on imipenem/cilastatin. Conclusion The prescription of imipenem/cilastatin at our setting was mostly appropriate to what is recommended in the guidelines and the literature, although a few cases could have been managed better. Dosage adjustment, however, was not as appropriate, mainly in patients who did not have a stable creatinine clearance.
eu_rights_str_mv openAccess
format article
id LAURepo_d40e76b8de1db69684150d01799fe912
identifier_str_mv 1178-6973
Kabbara, W. K., Nawas, G. T., & Ramadan, W. H. (2015). evaluation of the appropriateness of imipenem/cilastatin prescription and dosing in a tertiary care hospital. Infection and drug resistance, 8, 31.
language_invalid_str_mv en
network_acronym_str LAURepo
network_name_str Lebanese American University repository
oai_identifier_str oai:laur.lau.edu.lb:10725/4482
publishDate 2015
repository.mail.fl_str_mv
repository.name.fl_str_mv
repository_id_str
spelling Evaluation of the appropriateness of imipenem/cilastatin prescription and dosing in a tertiary care hospitalKabbara, Wissam K.Nawas, George T.Ramadan, Wijdan H.Background Imipenem/cilastatin is an antibacterial agent of the carbapenem class of β-lactams that is known to have an extremely wide spectrum of activity against Gram-positive, Gram-negative, aerobic, anaerobic, and even multidrug-resistant strains. The objective of this study was to evaluate the appropriate use of imipenem/cilastatin in a local tertiary care hospital. The study assessed the indication both empirically and after the culture results were available, the dose and dose adjustment in renal failure, as well as the incidence of seizure in hospitalized patients receiving imipenem/cilastatin. Methods This observational study was conducted in a tertiary care hospital over a 3-month period. The treatment of 100 patients with imipenem/cilastatin was evaluated both empirically and after culture results were available. Analysis of the appropriateness of imipenem/cilastatin indication, dose, and monitoring of seizure frequency was based on the package insert, updated published guidelines, and clinical judgment. Results Patients from internal medicine and intensive care units comprised approximately 50% of the population in the study. The patients received imipenem/cilastatin mainly for urinary tract infections (27%) or for sepsis of an unknown focus (22%). The use of imipenem/cilastatin empirically was appropriate in 97.2% (n=69/71) of the cases, and its use postculture in 86% of the cases. There were 29% of the patients who were not started on imipenem/cilastatin empirically. Four patients out of the 29 patients (13.8%) who were not started on imipenem/cilastatin empirically inappropriately received imipenem/cilastatin post-culture results. Thirty-three patients (33%) were not dosed appropriately, 30 of whom had renal impairment and creatinine clearance fluctuations. Only one patient developed a seizure while on imipenem/cilastatin. Conclusion The prescription of imipenem/cilastatin at our setting was mostly appropriate to what is recommended in the guidelines and the literature, although a few cases could have been managed better. Dosage adjustment, however, was not as appropriate, mainly in patients who did not have a stable creatinine clearance.PublishedN/A2016-10-03T08:10:14Z2016-10-03T08:10:14Z20152016-10-03Articleinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article1178-6973http://hdl.handle.net/10725/4482http://dx.doi.org/10.2147/IDR.S78633Kabbara, W. K., Nawas, G. T., & Ramadan, W. H. (2015). evaluation of the appropriateness of imipenem/cilastatin prescription and dosing in a tertiary care hospital. Infection and drug resistance, 8, 31.http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.phphttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4378284/enInfection and Drug Resistanceinfo:eu-repo/semantics/openAccessoai:laur.lau.edu.lb:10725/44822021-03-19T10:03:21Z
spellingShingle Evaluation of the appropriateness of imipenem/cilastatin prescription and dosing in a tertiary care hospital
Kabbara, Wissam K.
status_str publishedVersion
title Evaluation of the appropriateness of imipenem/cilastatin prescription and dosing in a tertiary care hospital
title_full Evaluation of the appropriateness of imipenem/cilastatin prescription and dosing in a tertiary care hospital
title_fullStr Evaluation of the appropriateness of imipenem/cilastatin prescription and dosing in a tertiary care hospital
title_full_unstemmed Evaluation of the appropriateness of imipenem/cilastatin prescription and dosing in a tertiary care hospital
title_short Evaluation of the appropriateness of imipenem/cilastatin prescription and dosing in a tertiary care hospital
title_sort Evaluation of the appropriateness of imipenem/cilastatin prescription and dosing in a tertiary care hospital
url http://hdl.handle.net/10725/4482
http://dx.doi.org/10.2147/IDR.S78633
http://libraries.lau.edu.lb/research/laur/terms-of-use/articles.php
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4378284/